|
O.A. Polyakova, A.V. Dubinina, S.S. Telkova, Yu.A. Isaakyan, O.D. Ostroumova
Atrial fibrillation and anemia: what do we know and how to approach therapy?
|
№1-2 / 2023
|
|
A.E. Bagriy, O.A. Prikolota, A.V. Prikolota, E.S. Mikhailichenko, I.A. Golodnikov, O.N. Bagriy, K.A. Kotova
Clinical effects of dapagliflozin in patients with type 2 diabetes mellitus and paroxysmal atrial fibrillation
|
№11-12 / 2022
|
|
A.V. Tarantsova
Features of the management and follow-up of a “difficult” comorbid elderly patient with COVID-19 complications: a clinical case
|
№3 / 2022
|
|
A.I. Tarzimanova, E.E. Bykova
Antiarrhythmic therapy for atrial fibrillation in patients with the novel SARS-CoV-2 coronavirus infection: how to make the right choice?
|
№13 / 2021
|
|
O.D. Ostroumova (1, 2), A.I. Kochetkov (1), S.V. Batyukina (1), N.L. Lyakhova (3)
Approaches to choosing a direct oral anticoagulant in the treatment of polymorbid patients with atrial fibrillation
|
№3 / 2020
|
|
I.G. Gordeev (1), N.A. Volov (1), M.N. Arefiev (2), R.S. Ilchenko (2)
QRS complex fragmentation in ST-segment elevation myocardial infarction: a clinical case
|
№9 / 2019
|
|
M.N. Kalinin (1, 2)
Prediction of the probability of hemorrhagic transformation to clarify the possible timing of initiation of anticoagulant therapy in patients with ischemic stroke and atrial fibrillation
|
№3 / 2019
|
|
L.B. Novikova, A.P. Akopyan, Kh.M. Mustafin, N.S. Khabibrakhmanova, I.I. Kayumova
RISK FACTORS FOR CEREBROVASCULAR DISEASES IN NEUROGERIATRY
|
№9 / 2017
|
|
I.A. Zolotovskaya, I.L. Davydkin
CHANGES IN ARTERIAL STIFFNESS AND ENDOTHELIAL DYSFUNCTION ON THE BACKGROUND OF ANTICOAGULANT THERAPY AFTER CARDIOEMBOLIC STROKE IN PATIENTS WITH ATRIAL FIBRILLATION
|
№6 / 2017
|
|
D.A. Napalkov, A.A. Sokolova
ANTICOAGULATION WITH DIRECT ORAL ANTICOAGULANTS BEYOND CLINICAL RECOMMENDATIONS: DIFFICULT CHOICE OF CLINICIANS AND PERSONALIZED APPROACH TO TREATMENT
|
№13 / 2016
|
|
A.A. Sokolova, I.L. Tsarev, D.A. Napalkov, V.A. Sulimov
MANAGEMENT OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE SETTINGS OF ANTICOAGULANT THERAPY CONTROL OFFICE: PROLONGED EFFECTIVE AND SAFE USE OF ANTICOAGULATION
|
№6 / 2016
|
|
M.G. Glezer
NEW ORAL ANTICOAGULANTS IN THE PREVENTION OF VENOUS THROMBOSIS AND THROMBOEMBOLISM: FOCUS ON RIVAROXABAN
|
№13 / 2014
|
Русский
